Dosimetric impacts of cone-beam computed tomography (CBCT)-based anatomic changes in intensity-modulated radiotherapy for cervical cancer
Original Article

Dosimetric impacts of cone-beam computed tomography (CBCT)-based anatomic changes in intensity-modulated radiotherapy for cervical cancer

Han Yang1^, Xiujuan Zhao2, Yang He1, Xia Tan1, Haiyan Peng1, Mingsong Zhong1, Qicheng Li1, Xianfeng Liu1, Yanan He1, Huanli Luo1, Fu Jin1

1Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China; 2Department of Gynecological Oncology, Chongqing University Cancer Hospital, Chongqing, China

Contributions: (I) Conception and design: H Yang, H Luo, F Jin; (II) Administrative support: H Luo, F Jin; (III) Provision of study materials or patients: H Luo, X Zhao, Y He, H Peng, X Tan; (IV) Collection and assembly of data: H Yang, M Zhong, Q Li, X Liu, Y He; (V) Data analysis and interpretation: H Yang, H Luo, F Jin; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

^ORCID: 0000-0002-9988-3880.

Correspondence to: Huanli Luo. Department of Radiation Oncology, Chongqing University Cancer Hospital, 181 Hanyu Road, Shapingba District, Chongqing 400030, China. Email: guyexianxue@126.com; Fu Jin. Department of Radiation Oncology, Chongqing University Cancer Hospital, 181 Hanyu Road, Shapingba District, Chongqing 400030, China. Email: jfazj@126.com.

Background: To evaluate the effects of dose to tumors and organs at risk (OARs) on inter-fractional anatomic changes.

Methods: We evaluated nine patients with cervical cancer treated with intensity-modulated radiotherapy (IMRT) (45 Gy in 25 fractions) using kV cone-beam computed tomography (CBCT) image guidance once or twice a week before treatment. For each patient, the original plan on the computed tomography (CT) image was copied to merged images, and then the fractional doses were calculated. Subsequently, deformable accumulated doses were obtained by summing the fractional absolute doses into a single dose in MIM Maestro software. The volume changes in the target and OARs were compared between the original CT and merged CBCT images, and the differences in the fractional and accumulated doses were also evaluated.

Results: Sixty-nine merged CBCT images were obtained and analyzed in this study. For the target areas, the volume changes in the clinical target volume (CTV) and planning target volume (PTV) reached −18.05% and −24.11% at most, respectively. The fractional D2% of the CTV and PTV was generally higher than the original plans, and the accumulated deviations were 2.27%±0.82% (P<0.01) and 2.42%±1.28% (P<0.01), respectively. The fractional D98% of the PTV was underdosed up to 18.28% for 78% of patients, and the accumulated deviations were −2.06% to −17.29% (P<0.05). For the OARs, the bladder volume changes were the most dramatic, reducing up to 93.60%. The fractional Dmean and D2cc of the bladder were generally higher than the original plans, and there were significant differences in their accumulated values (P<0.05). There was no obvious trend of rectal volume change with −69.65% to 74.20%. The rectum Dmean and D2cc of the accumulated were not significantly different from the planned dose (P>0.05).

Conclusions: For patients with cervical cancer, the changes in bladder and rectal volume were greater than in the target volume. Although the volume changes in the bladder and rectum had no significant effect on D98% of the CTV and PTV, they had a significant effect on their own D2cc and the D2% of the CTV and PTV. More attention should be paid to the volume changes in the bladder and rectum in clinical work.

Keywords: Merged cone-beam computed tomography image (merged CBCT image); CBCT-based dose calculation; anatomic changes; deformation dose; dosimetric uncertainties


Submitted Nov 25, 2022. Accepted for publication Dec 19, 2022. Published online Dec 01, 2022.

doi: 10.21037/atm-22-6157


Highlight box

Key findings

• We found that if the volume of the bladder and rectum were not strictly controlled in the radiotherapy of patients with cervical cancer, their changes were very large. It could significantly increase the CTV D2%, and it will also have a significant impact on the bladder and rectum’s own D2cc.

What is known and what is new?

• Anatomic changes during the treatment course are one of the leading contributors of delivered dose uncertainties in radiotherapy.

• In this study, we combined three CBCT images which can cover the entire pelvic cavity and contains all the information about the target and OARs in radiotherapy for cervical cancer.

What is the implication, and what should change now?

• The merged CBCT data in this study provides a suitable approach in ART that may be useful clinically to respond to the daily anatomy variations in cervical cancer patients.


Introduction

Intensity-modulated radiotherapy (IMRT) is an advanced three-dimensional irradiation technology developed in the past 20 years. It is capable of creating highly conformal dose distributions with sparing of normal tissues and have been widely used in cervical cancer radiotherapy (1). It has been reported that IMRT can reduce the dose received by the bladder, rectum, and small intestine during adjuvant radiotherapy after radical hysterectomy for cervical cancer. It can also significantly reduce gastrointestinal and urinary complications and hematological adverse reactions, and improve the tumor control rate and survival status of patients (2,3). However, anatomic changes (such as the different filling status of the bladder and rectum) during the treatment course are one of the leading contributors of delivered dose uncertainties in radiotherapy, potentially causing underdosage to the targets or overdosage to organs at risk (OAR) relative to the planned dose distribution (4-6). Therefore, it is meaningful to apply image-guided radiation therapy (IGRT) and adaptive radiotherapy (ART) (7-9).

Cone-beam computed tomography (CBCT) either a kilovoltage beam delivered using an additional x-ray tube mounted on the linac, to image the object from multiple projection angles and reconstruct a 3D image using the projected images. CBCT improves the repeatability of patient positioning compared with conventional two-dimensional image guidance (10). But the matching of planning CT and CBCT images cannot fully reflect the anatomical changes of all organs simultaneously. Therefore, some scholars have explored the dosimetric changes caused by the volume and morphological changes of the target and OARs based on CBCT image dose calculation in cervical and pancreatic cancer radiotherapy (11). Unfortunately, the limited field of view (FOV) range of the CBCT hardware equipment cannot contain all the information about the target and OARs in cervical cancer radiotherapy, and the areas beyond the range of CBCT can only be simulated by the original image registration. Image stitching provides a good method to solve this problem.

In this study, we combined three CBCT images to generate a merged image with a scan length of 46 cm. This image can cover the entire pelvic cavity and contains all the information about the target and OARs in radiotherapy for cervical cancer. Subsequently, the changes in volume during treatment and their effect on the fractional and accumulated dose were analyzed for the target and OARs on merged CBCT images. The inter-fractional morphological changes in organs were also observed. According to our literature review, studies on the effect of volume change on fractional dose and accumulated dose in treatment using image stitching are currently scarce. We present the following article in accordance with the MDAR reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-6157/rc).


Methods

Patient population

This study included nine patients with stage IA1–IIIC1r cervical cancer (International Federation of Gynecology and Obstetrics) who received IMRT in the Chongqing University Cancer Hospital. Of these, four patients underwent radical hysterectomy, four received lymph node dissection, and one did not have surgery. The basic information about these patients is summarized in Table 1. None of the patients had radiotherapy contraindications, and all voluntarily underwent merged CBCT scans once or twice weekly. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Chongqing University Cancer Hospital (No. CZLS2021048-A) and informed consent was taken from all the patients.

Table 1

Patient information

Patient ID Age (years) Height (cm) Weight (kg) Histology and stage Surgery Adjuvant treatment
1 66 142 52 Squamous cell carcinoma IA1 Radical hysterectomy Concurrent chemoradiotherapy
2 28 160 46.5 Adenosquamous cell carcinoma IB2 Radical hysterectomy Concurrent chemoradiotherapy
3 50 155 59 Squamous cell carcinoma IIIC1p Lymph node dissection Concurrent chemoradiotherapy
4 56 153 51 Adenocarcinoma IB Radical hysterectomy Concurrent chemoradiotherapy
5 76 155 50 Squamous cell carcinoma IIIB None Concurrent chemoradiotherapy
6 53 155 51 Squamous cell carcinoma IIIC1r Lymph node dissection Concurrent chemoradiotherapy
7 59 155 61 Squamous cell carcinoma IIIC1p Lymph node dissection Concurrent chemoradiotherapy
8 35 158 54 Squamous cell carcinoma IIA1 Radical hysterectomy Concurrent chemoradiotherapy
9 51 155 61 Squamous cell carcinoma IIIC1r Lymph node dissection Concurrent chemoradiotherapy

Positioning and contouring

All patients were placed in the supine position with both hands raised and fixed with a thermoplastic membrane. Half an hour before the positioning scan, the patients were instructed to empty their bladders and then drink 250 mL of water. No instructions on rectal filling were given to these patients. The computed tomography (CT) scanning (Big Bore; Philips Brilliance, Holland) was performed for each patient at 5 mm slice thickness with a scope from the diaphragm level to 4 cm below the ischial tubercle. The CT images were imported to the Eclipse treatment planning system (TPS) (Varian Medical Systems, Version 15.6, Inc., USA) and prepared for contouring.

The target and OARs were delineated by the same experienced radiation oncologist according to the International Commission on Radiation Units and Measurement (ICRU) Report 62. The clinical target volume (CTV) of the pelvic cavity included the whole uterus (if present), the vaginal stump, 1/2 of the upper segment of the vagina, the parauterine/paravaginal soft tissue, the pelvic lymphatic drainage area (including the common iliac, external iliac, internal iliac, obturator, and presacral lymph node areas), the upper boundary to the level of the 4th to 5th lumbar vertebrae, and the lower boundary to the lower edge of the obturator. The planning target volume (PTV) was generated from the CTV, adding a 5 mm margin with all expansion to offset setup uncertainties. Then, the small intestine, rectum, bladder, and femoral head were contoured as the OARs. Among them, the small intestine included the intestinal tube and its surrounding mesenteric tissue; the upper boundary of the rectum was the junction of the rectum and the sigmoid colon, and the lower boundary was the anus. The contour of the bladder reflects its filling state.

Treatment planning

The IMRT plans for all patients were designed on the Eclipse TPS with 6 MV photon beams generated by an EDGE linear accelerator with a Millenium 120 MLC (Varian Medical Systems). The IMRT plans contained seven co-planar fields (210°/260°/310°/0°/50°/100°/150°). The dose prescribed to the PTV was 45 Gy in 25 daily fractions. The planning goal was to achieve 95% or more of the PTV receiving the prescription dose, with the maximum dose point not exceeding 110% of the prescription dose. The dose constraints of the OARs were based on the Radiation Therapy Oncology Group-1203 Randomized Phase III trial guidelines.

In all plans, photon optimizer (PO) algorithms were used for optimizations, and the anisotropic analytical algorithm (AAA) was applied for the final dose calculations. The resolution used for the dose calculation was 2.5 mm in all directions. The maximum speed of the multi-leaf collimator (MLC) motion was 2.5 cm/s. In addition, the jaw tracking method was also used. In this method, the jaw moves with the changes in MLC position in real-time while the beam is on. This technique reduces the opening size of the jaw as much as possible to minimize transmission and leakage, thus reducing the normal tissue dose (12-14).

Image acquisition and merging

All patients underwent CBCT scans prior to treatment once or twice a week using a Varian On-board Imager Spotlight protocol. The scanning parameters were as follows: 360° rotation scan, 120 kV, FOV 26 cm in diameter, and 5 mm slice thickness. For each image guidance, we collected three CBCT images; one on the planning center, which was used for 3D matching, and the other two images generated on the 15 cm movement of the planning center in the direction of the advance and retreat bed. The area covered by both individual volumes was irradiated twice. This overlap led to visible artifacts in the border region between the two volumes. The image information in the overlapping area was processed and merged by keeping the brighter [more Hounsfield units (Hus)] voxel for each single voxel. Then, the merged images were obtained, which covered the entire pelvic cavity with a scan length of 46 cm.

Volume correction

The target and OARs on the merged CBCT images were delineated by the same experienced radiation oncologist, according to the ICRU Report 62. Nevertheless, there were still differences in artificial delineation caused by the influence of the CBCT image quality. To solve this problem, the humeral heads were used as a reference to correct the volume. The correction formula was as follows:

Vcorrected=Vcontour×(1+ΔVFemoralhead/100)

ΔVFemoralhead=(ΔVFemoralheadR+ΔVFemoralheadL)/2

ΔVFemoralhead R/L=(VCBCTVCT)/VCT×100

Here, Vcorrected is the corrected volume; Vcontour is the original contour volume; ΔVFemoral head R/L is the volume deviation of the right or left femoral heads between each fractional merged CBCT and original CT image; ΔVFemoral head is the mean volume deviation of the femoral heads; VCBCT and VCT are the volumes of the corresponding structures in CBCT and CT, respectively.

For a more accurate dose calculation, the contour lines of the target and OARs on each merged CBCT image were corrected by calculating the equivalent spherical radius Rcontour and Rcorrected before and after volume correction through Vcontour and Vcorrected. According to the difference between the two radii, the structures were placed outward or inward in the TPS.

CBCT-based dose calculation

Before CBCT-based dose calculation, a calibration of the HUs to electron density (ED) was performed for inhomogeneity corrections using the Advanced Electron Density Phantom Model 1467 (Gammex Inc., USA) (Figure 1A) (15). This phantom and its material insert were scanned with the standard clinical protocol (Figure 1B). The HU of each insert was extracted within a region of interest (ROI) and assigned to the known related relative ED to generate a calibration curve for the TPS (Figure 1C).

Figure 1 Hounsfield units to electron density calibration. (A) Advanced Electron Density Phantom Model 1467. (B) CBCT image for the phantom. (C) The calibration curve of HUs to ED. CBCT, cone-beam computed tomography; HUs, Hounsfield units; ED, electron density.

Subsequently, the merged CBCT images for each patient were matched onto the planning CT image according to the bony anatomy using 3D/3D matching. The original plan was copied to the merged CBCT image, and then the fractional delivered doses were calculated and compared with the original planned dose.

The calculation process of the CBCT-based accumulated delivered dose is presented in Figure 2, taking Patient 8 as an example. In this process, the status of the treatment fraction without CBCT scanning prior to treatment was replaced by the last merged CBCT image to simulate the daily treatment status of patients to the maximum extent. A free deformable image registration (DIR) algorithm (VoxAlignTM) based on the image intensity from MIM Maestro was used to map the voxels (dose) from one merged image to another merged image. The sequence of dose accumulation by image registration (Figure 2) was to superimpose the 1st and 2nd CBCT doses onto the 2nd CBCT image, then superimpose the superimposed results with the 3rd CBCT dose onto the 3rd CBCT image, and so on. The final deformation accumulated dose was obtained.

Figure 2 The calculation process of the CBCT-based accumulated delivered dose, taking Patient 8 as an example. CBCT, cone-beam computed tomography.

The CBCT-based delivered doses were compared with the planned doses for each treatment day and the accumulated doses for the entire treatment. CTV D98%, CTV D2%, PTV D98%, PTV D2%, and D2cc and Dmean of the OARs were compared between the original plan and actual accumulated delivery.

Statistical analysis

The paired differences in CTV, PTV, and OAR metrics were analyzed by comparing the planned and accumulated doses using SPSS 19.0 statistical software (SPSS, Chicago, IL, USA). According to the Shapiro-Wilk test, some data of the accumulated doses did not follow a normal distribution, so the data in this paper are represented by the median and upper and lower quartiles [M (P25, P75)]. The multi-sample nonparametric rank sum test was used, and the Kruskal-Wallis test was performed. The effect of volume change on the fractional dose was analyzed by Pearson correlation. A P value <0.05 was considered statistically significant.


Results

Fractional volume changes of the target and OARs

Sixty-nine merged CBCT images covering the entire pelvic cavity were obtained in this study. Compared with the original CT images, the fractional volume changes of the target and OARs are shown in Figure 3A-3D, and the statistical results are shown in Table 2. The differences made by manual delineation based on CBCT are shown in Figure 3E and 3F, with a mean range from −2.36% to 0.93%.

Figure 3 Fraction changes in the target and OARs during treatment: (A) CTV; (B) PTV; (C) bladder; (D) rectum; the differences made by manual delineation are shown in (E) and (F). The percentage of volume difference was calculated by the volume on merged CBCT images minus the original CT images and then divided by the volume on the original CT images. CTV, clinical target volume; PTV, planning target volume; OARs, organs at risk; CBCT, cone-beam computed tomography.

Table 2

The difference in volume and dose between merged CBCT images and original CT images

No. CTV PTV Bladder Rectum
ΔV ΔD2% ΔD98% ΔV ΔD2% ΔD98% ΔV ΔDmean ΔD2cc ΔV ΔDmean ΔD2cc
1
   Mean −7.67 3.69 2.55 −6.58 3.62 -4.80 −89.28 15.78 0.88 −50.27 8.72 3.98
   SD 3.25 0.32 0.42 1.71 0.27 3.76 4.60 9.57 2.74 19.18 8.38 0.27
2
   Mean −2.58 2.83 0.86 1.38 2.74 −5.59 −39.02 2.41 2.56 −1.82 6.05 3.35
   SD 1.72 0.42 0.54 1.33 0.35 3.77 31.02 3.56 0.58 10.34 3.03 0.19
3
   Mean −6.07 3.59 0.38 2.09 3.62 −11.45 −57.79 29.37 5.82 1.43 −4.17 2.54
   SD 2.97 0.31 2.07 1.41 0.32 4.78 20.32 15.06 0.27 11.01 5.97 0.52
4
   Mean −1.63 1.07 0.00 −9.62 1.07 −0.84 −55.66 4.42 0.00 11.13 −8.90 −0.79
   SD 1.39 0.66 0.41 0.96 0.64 0.97 15.34 4.98 1.56 33.86 5.62 2.62
5
   Mean −0.41 3.50 1.50 −3.68 3.41 −8.87 −68.09 22.95 2.70 −8.31 14.36 5.12
   SD 1.92 0.27 0.39 1.50 0.38 3.81 21.49 8.18 1.54 15.76 11.98 0.58
6
   Mean −14.32 2.50 1.88 −8.78 2.51 0.48 18.55 15.74 2.89 6.84 5.64 2.84
   SD 3.33 0.21 0.27 2.23 0.22 1.12 67.87 6.63 0.27 18.18 6.46 1.15
7
   Mean −6.67 3.16 -0.83 −2.49 2.91 −7.09 −60.97 10.15 2.84 −57.76 −5.80 −2.99
   SD 6.31 0.79 2.00 4.38 0.78 3.24 13.47 6.08 1.03 13.74 5.64 2.08
8
   Mean −8.43 2.50 −2.00 −18.84 2.84 −2.91 −73.59 −3.49 −0.62 −31.31 9.92 3.25
   SD 5.70 0.97 3.15 3.04 0.28 4.75 17.40 4.15 1.51 15.39 5.29 0.62
9
   Mean −13.58 4.06 2.32 −8.34 4.00 −1.87 −85.12 10.11 1.47 −23.99 16.02 6.37
   SD 1.90 0.41 0.22 1.45 0.42 1.26 6.41 5.16 1.19 6.95 7.01 0.58

CBCT, cone-beam computed tomography; CT, computed tomography; CTV, clinical target volume; PTV, planning target volume; SD, standard deviation.

In general, the results of the study were not affected by the patient's surgical status. The CTV and PTV volume changes ranged from −24.11% to 4.29%. The most significant change was found in the bladder volume, and this reduction was as high as 93.60%, except for Patient 6. There was no significant trend in rectal volume, ranging from −69.65% to 74.20%. As an example, the contours of the target and OARs in each fractional merged CBCT image of Patient 2, mapped to the original CT by registration, are shown in Figure 4. For Patient 2, the bladder profile changed significantly in the sagittal plane compared with the coronal plane and cross-section, and the volume changes of the target and other organs were small.

Figure 4 Contour differences in the target and OARs between fractional merged CBCT and original CT for Patient 2. (A) Cross section; (B) coronal plane; (C) sagittal plane. The magenta line is CTV, red is PTV, cyan is the rectum, green is the bladder, orange is the right femoral head, blue is the left femoral head, and the green crosshair is the positioning origin. OARs, organs at risk; CBCT, cone-beam computed tomography; CT, computed tomography; CTV, clinical target volume; PTV, planning target volume.

Evaluation of merged CBCT-based fractional delivered dose

Figure 5 shows the fractional dose change of the CTV, PTV, bladder, and rectum for each patient during fractional treatment relative to the original plan. The statistical results are shown in Table 2. As shown in Figure 5, the fractional D2% of the CTV and PTV was higher than the original plan, and the maximum was 4.52%. The average deviation of the CTV D98% was −2.00% to 2.55% for all patients. Except for Patients 6 and 8, the fractional D98% of the PTV was underdosed up to 18.28%. For the bladder, the fractional Dmean and D2cc were in most cases higher than the original plan. The average deviation of the rectum Dmean was −9.92% to 16.02% for all patients, and the changes on D2cc were –2.99% to 6.37%.

Figure 5 Fraction changes in the target and OARs during treatment: (A) CTV D2%; (B) CTV D98%; (C) PTV D2%; (D) PTV D98%; (E) Bladder Dmean; (F) Bladder D2cc; (G) Rectum Dmean; (H) Rectum D2cc. CTV, clinical target volume; PTV, planning target volume; OARs, organs at risk.

Evaluation of merged CBCT-based accumulated delivered dose

The differences between the target and OARs in the accumulated delivered doses and planned doses are shown in Table 3 and Figure 6. The accumulated relative deviations on D2% of the CTV and PTV were 2.27%±0.82% (P<0.01) and 2.42%±1.28% (P<0.01), respectively. For the dose coverage of the target, the CTV D98% deviation was within −6.59% to 2.18%, and there was no significant difference (P>0.05). Overall, the PTV D98% was undervalued by 2.06% to 17.29%, and there was a statistically significant difference (P<0.05). As shown in Table 3, the accumulated Dmean and D2cc of the bladder were significantly higher than the planned dose (P<0.05), and there was no significant difference for the rectum accumulated Dmean (P>0.05).

Table 3

Results of the dosimetric comparison for targets and OARs between planned doses and merged CBCT-based accumulated doses [M (P25, P75)]

Structure Dose metric Median planned dose,
Gy (P25, P75)
Median accumulated dose,
Gy (P25, P75)
Z value P value
CTV D2% 48.12 (47.62, 48.16) 49.16 (48.76, 49.42) −2.668 0.008
D98% 45.88 (45.63, 46.22) 44.70 (43.62, 46.63) −1.820 0.069
PTV D2% 48.11 (47.60, 48.14) 49.17 (48.68, 49.49) −2.666 0.008
D98% 44.31 (44.21, 44.58) 39.28 (37.02, 42.76) −2.666 0.008
Bladder Dmean 32.29 (31.09, 36.91) 37.78 (33.96, 43.14) −2.310 0.021
D2cc 47.75 (46.99, 48.09) 48.45 (47.71, 48.89) −2.100 0.036
Rectum Dmean 35.63 (30.59, 37.82) 35.51 (32.80, 37.94) −0.415 0.678
D2cc 46.70 (45.97, 47.33) 47.89 (47.17, 48.55) −1.601 0.109

OARs, organs at risk; CBCT, cone-beam computed tomography; CTV, clinical target volume; PTV, planning target volume.

Figure 6 The relative deviations in the target and OARs between the accumulated delivered doses and planned doses. CTV, clinical target volume; PTV, planning target volume; OARs, organs at risk.

Effect of volume change on the fractional dose delivered

The effects of volume changes in the target and OARs on the fractionated delivered dose are shown in Table 4. The change in CTV volume only affected the dosimetric parameters of the PTV. The volume changes in the PTV had a greater effect on dose than the other three but did not have any effect on the rectal dose. Changes in the volume of the bladder and rectum had significant effects on their own D2cc and also had significant effects on the CTV D2% and PTV D2%.

Table 4

Effect of volume change on fractional dose delivered [r (P)]

Parameter ΔVCTV (%) ΔVPTV (%) ΔVBladder (%) ΔVRectum (%)
ΔD2%, CTV −0.180 (0.140) 0.299 (0.013) −0.265 (0.028) −0.295 (0.014)
ΔD98%, CTV −0.017 (0.893) 0.302 (0.012) 0.141 (0.247) 0.102 (0.402)
ΔD2%, PTV −0.290 (0.016) 0.173 (0.155) −0.311 (0.009) −0.302 (0.012)
ΔD98%, PTV −0.265 (0.028) −0.464 (0.000) 0.225 (0.063) 0.105 (0.389)
ΔDmean, Bladder −0.077 (0.528) 0.407 (0.001) 0.111 (0.364) 0.111 (0.365)
ΔD2cc, Bladder −0.030 (0.804) 0.615 (0.000) 0.281 (0.019) 0.227 (0.061)
ΔDmean, Rectum −0.169 (0.165) −0.194 (0.110) −0.181 (0.136) −0.005 (0.968)
ΔD2cc, Rectum −0.162 (0.183) −0.103 (0.401) −0.133 (0.275) 0.300 (0.012)

CTV, clinical target volume; PTV, planning target volume.


Discussion

In this study, the merged CBCT reflected the whole pelvic state of the patient during treatment. Dosimetric uncertainties are mainly caused by changes in the shape and volume of the patient's organs. We found that the fractional volumes of the CTV, PTV, bladder, and rectum were significantly different, which caused many patients to receive higher doses to the OARs. Moreover, both the fractional doses and the accumulated doses of the CTV and PTV were underdosed compared with the original plan.

The target area of external irradiation for cervical cancer is located in the abdominal and pelvic cavities. The target area positions are easily affected by the bladder-filling state and intestinal movements (16-18). In this study, the patients emptied their bladders half an hour before positioning and drank 250 mL of water but did not strictly follow the doctor's instructions during the actual follow-up treatment. It can be seen from Table 2 and Figure 3 that the volume of the bladder and rectum changed greatly, reaching −90% and −70%, respectively, and their volumes changed mainly in the direction of head-to-foot and abdomen-to-back (Figure 4). The change in bladder volume was generally reduced except for Patient 6. This patient did not strictly follow the doctor’s advice during localization, which led to insufficient bladder filling in the localization CT, contrary to other patients. Although the PTV is obtained by uniformly expanding the CTV by 0.5 cm, the volume change trend of the CTV and PTV in each patient was inconsistent. For example, the CTV volume of Patient 3 during treatment was smaller than the original CT image, but the PTV volume was larger than the original CT image (Figure 3A,3B). In this instance, we considered that the patient's organs had changed shape; the contour difference of the CTV in the head-to-foot direction in the patient will cause this kind of situation when the CTV is expanded by Boolean operation. As the only rigid structure in this region, the femoral head has the smallest volume change with a range of −3% to 2%, mainly due to the poor image quality of CBCT compared with CT, and the edge recognition is not clear enough. So, the humeral heads were used as a reference to correct the volume.

Changes in the shape and volume of organs in patients will bring about differences in dosimetry. Many studies have reported the necessity of adaptive strategies that consider the inter-fractional variations in bladder and rectum filling (19-21). It was found in this study that changes in the volume of the bladder and rectum had significant effects on their own D2cc, and both also had significant effects on the CTV D2% and PTV D2% (Table 4). It can be seen from Figure 5 that all the fractional CTV D2% and PTV D2% doses were higher than the original plan, and the fractional PTV D98% was lower than the original plan. Despite the protection of the PTV, some fractional CTV D98% doses in Patients 3, 4, 7, and 8 were lower than the original plan. This indicates that differences in bladder and rectum filling, and the deformation of the target volume caused by image guidance based on CBCT bone matching, cannot guarantee the daily dose coverage of the target volume, and the homogeneity of the target volume dose deteriorates. Figure 7 shows that the rectum volume of Patient 8 was increased, and the bladder volume was significantly reduced during the 6th merged CBCT, resulting in the overall deviation of the target area toward the abdomen. When the offset distance is greater than 5 mm, the CTV breaks away from the protection of external expansion, and the dose cannot completely cover the CTV at this time. The dose homogeneity of the target area deteriorates, mainly due to tissue edema caused by treatment and gas pockets in the digestive tract that increase the density differences between tissues. Hot areas are easily formed in the air cavity area, and the increase of D2% leads to uneven dose distribution. A previous study has also reported the increase in dose due to the gas pocket effect (22). These variations in delivered doses are considered as the variation of Total Energy Released per unit Mass (TERMA) and deformations of the dose kernel in heterogeneous media. So, artifacts and cavitation affect the accuracy of CBCT-based dose calculations.

Figure 7 Example of dose distribution changes in the sagittal position for Patient 8. (A) The 95% prescription dose distribution in the original CT image. (B) The 95% prescription dose distribution in the merged CBCT image for fraction 6. The magenta line is CTV, the red line is PTV, the cyan line is the rectum, the green line is the bladder, and the green crosshair is the positioning origin. CBCT, cone-beam computed tomography; CTV, clinical target volume; PTV, planning target volume.

When comparing dose differences between planned doses and merged CBCT−based accumulated doses, consistent fractional dose differences resulted in significant accumulated dose differences (Table 3, Figure 6). They indicated that the D2% accumulated CTV and PTV dose was higher than the original plan (P<0.05), and the accumulated PTV D98% was underdosed (P<0.05), which were consistent with the fractional dose difference and showed a statistical difference. Although some fractional CTV D98% doses were lower than the original plan, there was no statistical difference in the CTV D98% between the accumulated dose and the original plan dose due to the existence of the PTV (P>0.05). This work clarified that the CTV extension of 5 mm in our institution ensures the CTV dose coverage and meets the requirements of clinical treatment. For OARs, the bladder fractional dose was generally increased except for Patient 8, and the accumulated doses of the bladder Dmean and D2cc were significantly higher than the planned dose (P<0.05). This problem of bladder overdosing is not only due to patient compliance but also a reduction in urine volume during treatment because of bladder function degeneration with increased radiotherapy times (23). It showed that a small organ volume results in higher doses and larger side effects. Therefore, it is more advantageous to treat patients with a moderate bladder protocol to ensure treatment repeatability and reduce toxicity (24,25). Although there was no significant difference in the rectum Dmean between planned doses and merged CBCT-based accumulated doses (P<0.05), the fractional rectum Dmean in Patients 1, 2, 5, 6, 8, and 9 was higher than that in the original plan, with a maximum of 34%. It can be seen that there is significant uncertainty in the fractional dose of IMRT for cervical cancer. ART should be used to ensure delivery accuracy of the target volume and OARs. It can eliminate the effects of dosimetry on patient anatomic changes and gas pocket fluctuations in planning CT and treatment. ART based on periodical replanning has been reported as beneficial for patients with various diseases (26-28).

Our work had potential limitations. The accumulated dose obtained in this study was not based on the daily CBCT; instead, we used the merged CBCT performed 1 to 2 times a week to simulate the adjacent treatment fraction status. Therefore, the difference in accumulated dose in this study cannot accurately reflect the dose change during treatment; it only provided us with a reference for the trend in accumulated dose changes in the target area and OARs. Daily imaging scans were not selected in this study because of the additional imaging dose. In clinical practice, the imaging dose in radiation therapy has traditionally been ignored due to its low magnitude and frequency compared to the therapeutic dose used to treat patients. In fact, daily imaging results in additional doses delivered to the patient. A previous study indicated that the use of a daily standard mode CBCT for a 35-fraction treatment could result in up to 1.5–2 Gy to some critical organs and an effective dose of 600 to 800 mSv to the body, which may induce an additional secondary cancer risk of 3–4% (29,30). To ensure the completeness and safety of image data acquisition, we will add an additional image dose to the treatment plan using the Monte Carlo (MC) modeling method in future studies. The MC simulation and verification of the imaging beams has been performed by Ding et al. using the Varian On-Board Imaging (OBI) unit (31,32).


Conclusions

In conclusion, we found that if the volume of the bladder and rectum were not strictly controlled in the radiotherapy of patients with cervical cancer, their changes were very large. Although the effect on the CTV D98% was not significant, it could significantly increase the CTV D2%, and it will also have a significant impact on the bladder and rectum's own D2cc. Therefore, more attention should be paid to the volume changes in the bladder and rectum in clinical work. Our recommendation is to perform at least CBCT once a week for organ anatomic changes monitoring plus daily verification of bladder filling with a bladder scan (24). Finally, the merged CBCT data in this study provides a suitable approach in ART that may be useful clinically to respond to the daily anatomy variations in cervical cancer patients. It offers a good possibility for evaluating the daily applied dose for the bladder and rectum.


Acknowledgments

Funding: This study was supported by the Chongqing Natural Science Foundation of China (No. cstc2021jcyj-msxmX0441) and the Joint Project of Chongqing Health Commission and Science and Technology Bureau (No. 2022DBXM005).


Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at https://atm.amegroups.com/article/view/10.21037/atm-22-6157/rc

Data Sharing Statement: Available at https://atm.amegroups.com/article/view/10.21037/atm-22-6157/dss

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-6157/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Chongqing University Cancer Hospital (No. CZLS2021048-A) and informed consent was taken from all the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Wang Y, Ballo MT, Hubler A, et al. Intensity-Modulated Versus Three-Dimensional Conformal Radiotherapy for Cervical Cancer: National Trend and Survival. Int J Radiat Oncol 2019;105:E339-40.
  2. Marjanovic D, Plesinac Karapandzic V, Stojanovic Rundic S, et al. Acute toxicity of postoperative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy. J BUON 2019;24:2347-54.
  3. Wortman BG, Post CCB, Powell ME, et al. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2022;112:390-9. [Crossref] [PubMed]
  4. Gort EM, Beukema JC, Matysiak W, et al. Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer. Radiother Oncol 2021;154:194-200. [Crossref] [PubMed]
  5. Tsujii K, Ueda Y, Isono M, et al. Dosimetric impact of rotational setup errors in volumetric modulated arc therapy for postoperative cervical cancer. J Radiat Res 2021;62:688-98. [Crossref] [PubMed]
  6. Niedzielski JS, Liu Y, Ng SSW, et al. Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance. Int J Radiat Oncol Biol Phys 2021;111:1298-309. [Crossref] [PubMed]
  7. de Crevoisier R, Lafond C, Mervoyer A, et al. Image-guided radiotherapy. Cancer Radiother 2022;26:34-49. [Crossref] [PubMed]
  8. Tan Mbbs Mrcp Frcr Md LT. Image-guided Adaptive Radiotherapy in Cervical Cancer. Semin Radiat Oncol 2019;29:284-98. [Crossref] [PubMed]
  9. Kong V, Hansen VN, Hafeez S. Image-guided Adaptive Radiotherapy for Bladder Cancer. Clin Oncol (R Coll Radiol) 2021;33:350-68. [Crossref] [PubMed]
  10. Nabavizadeh N, Elliott DA, Chen Y, et al. Image Guided Radiation Therapy (IGRT) Practice Patterns and IGRT's Impact on Workflow and Treatment Planning: Results From a National Survey of American Society for Radiation Oncology Members. Int J Radiat Oncol Biol Phys 2016;94:850-7. [Crossref] [PubMed]
  11. Utena Y, Takatsu J, Sugimoto S, et al. Trajectory log analysis and cone-beam CT-based daily dose calculation to investigate the dosimetric accuracy of intensity-modulated radiotherapy for gynecologic cancer. J Appl Clin Med Phys 2021;22:108-17. [Crossref] [PubMed]
  12. Feng Z, Wu H, Zhang Y, et al. Dosimetric comparison between jaw tracking and static jaw techniques in intensity-modulated radiotherapy. Radiat Oncol 2015;10:28. [Crossref] [PubMed]
  13. Kim JI, Park JM, Park SY, et al. Assessment of potential jaw-tracking advantage using control point sequences of VMAT planning. J Appl Clin Med Phys 2014;15:4625. [Crossref] [PubMed]
  14. Wu H, Jiang F, Yue H, et al. A comparative study of identical VMAT plans with and without jaw tracking technique. J Appl Clin Med Phys 2016;17:133-41. [Crossref] [PubMed]
  15. Hu CC, Huang WT, Tsai CL, et al. Practically acquired and modified cone-beam computed tomography images for accurate dose calculation in head and neck cancer. Strahlenther Onkol 2011;187:633-44. [Crossref] [PubMed]
  16. Ding S, Liu H, Wang B, et al. Inter- and Intrafraction Bladder and Rectum Motion in Patients With Cervical Cancer Under MR-Guided Radiotherapy on a 1.5T MR-Linac. Int J Radiat Oncol 2021;111:e612.
  17. Li X, Wang L, Cui Z, et al. Online MR evaluation of inter- and intra-fraction uterus motions and bladder volume changes during cervical cancer external beam radiotherapy. Radiat Oncol 2021;16:179. [Crossref] [PubMed]
  18. Jadon R, Pembroke CA, Hanna CL, et al. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clin Oncol (R Coll Radiol) 2014;26:185-96. [Crossref] [PubMed]
  19. Felici F, Benkreira M, Lambaudie É, et al. Adaptive Magnetic Resonance-Guided External Beam Radiation Therapy for Consolidation in Recurrent Cervical Cancer. Adv Radiat Oncol 2022;7:100999. [Crossref] [PubMed]
  20. Zhang Y, Zhang X, Li J, et al. Analysis of the Influence of Peripheral Anatomical Changes for CBCT-Guided Prostate Cancer Radiotherapy. Technol Cancer Res Treat 2021;20:15330338211016370. [Crossref] [PubMed]
  21. van de Schoot AJAJ, de Boer P, Visser J, et al. Dosimetric advantages of a clinical daily adaptive plan selection strategy compared with a non-adaptive strategy in cervical cancer radiation therapy. Acta Oncol 2017;56:667-74. [Crossref] [PubMed]
  22. Fidanzio A, Porcelli A, Azario L, et al. Quasi real time in vivo dosimetry for VMAT. Med Phys 2014;41:062103. [Crossref] [PubMed]
  23. Pearson D, Gill SK, Campbell N, et al. Dosimetric and volumetric changes in the rectum and bladder in patients receiving CBCT-guided prostate IMRT: analysis based on daily CBCT dose calculation. J Appl Clin Med Phys 2016;17:107-17. [Crossref] [PubMed]
  24. Luo H, Jin F, Yang D, et al. Interfractional variation in bladder volume and its impact on cervical cancer radiotherapy: Clinical significance of portable bladder scanner. Med Phys 2016;43:4412. [Crossref] [PubMed]
  25. Jin F, Luo HL, Zhou J, et al. A parameterized model for mean urinary inflow rate and its preliminary application in radiotherapy for cervical cancer. Sci Rep 2017;7:280. [Crossref] [PubMed]
  26. Roberts HJ, Huynh E, Williams CL, et al. Impact of Stereotactic MR-Guided Adaptive Radiation Therapy on Early Clinical and Dosimetric Outcomes in Patients With Pancreatic Cancer. Int J Radiat Oncol 2021;111:e72.
  27. Avgousti R, Antypas C, Armpilia C, et al. Adaptive radiation therapy: When, how and what are the benefits that literature provides? Cancer Radiother 2022;26:622-36. [Crossref] [PubMed]
  28. Dial C, Weiss E, Siebers JV, et al. Benefits of adaptive radiation therapy in lung cancer as a function of replanning frequency. Med Phys 2016;43:1787. [Crossref] [PubMed]
  29. Alaei P, Spezi E. Imaging dose from cone beam computed tomography in radiation therapy. Phys Med 2015;31:647-58. [Crossref] [PubMed]
  30. Kan MW, Leung LH, Wong W, et al. Radiation dose from cone beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys 2008;70:272-9. [Crossref] [PubMed]
  31. Ding GX, Coffey CW. Beam characteristics and radiation output of a kilovoltage cone-beam CT. Phys Med Biol 2010;55:5231-48. [Crossref] [PubMed]
  32. Ding GX, Duggan DM, Coffey CW. Accurate patient dosimetry of kilovoltage cone-beam CT in radiation therapy. Med Phys 2008;35:1135-44. [Crossref] [PubMed]

(English Language Editor: D. Fitzgerald)

Cite this article as: Yang H, Zhao X, He Y, Tan X, Peng H, Zhong M, Li Q, Liu X, He Y, Luo H, Jin F. Dosimetric impacts of cone-beam computed tomography (CBCT)-based anatomic changes in intensity-modulated radiotherapy for cervical cancer. Ann Transl Med 2022;10(24):1381. doi: 10.21037/atm-22-6157

Download Citation